Research programme: galectin inhibitors - La Jolla Pharmaceutical
Alternative Names: Galectin antagonists - La Jolla Pharmaceutical; Galectin-3 inhibitors - La Jolla Pharmaceutical; LJPC-201; LJPC-301Latest Information Update: 13 Mar 2025
At a glance
- Originator La Jolla Pharmaceutical Company
- Class Monoclonal antibodies; Small molecules
- Mechanism of Action Galectin 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure; Hepatic fibrosis; Solid tumours
Most Recent Events
- 13 Mar 2025 Discontinued for Heart failure in USA (PO)
- 13 Mar 2025 Discontinued for Hepatic fibrosis in USA (PO)
- 13 Mar 2025 Discontinued for Solid tumours in USA (Parenteral)